Neutrophil-to-lymphocyte ratio in XXXX .

@entity1 @entity135 @entity5 @entity957 @entity3 @entity1349
INTRODUCTION: The neutrophil-to-lymphocyte ratio (NLR) is an index of systemic inflammatory burden in @entity5 . An elevated NLR has been associated with poor prognosis in a number of @entity5 sites. We investigated its role in a cohort of @entity1 with locally advanced @entity135 . METHODS: Eligible @entity1 had primary @entity957 treated with chemoradiotherapy and a minimum follow-up of 12 months (unless deceased). NLR was analysed as <5 vs. >= 5 and above and below the median. The primary endpoint was @entity1349 ( @entity1349 ) and secondary endpoints @entity3 free survival and locoregional relapse free survival. Actuarial Kaplan-Meier statistics and log rank test were used. Univariate analysis for age (continuous), Eastern Cooperative Oncology Group performance status (0 vs. 1), gender (male vs. female), smoking (yes vs. no), American Joint Committee on @entity5 stage (III vs. IV) and NLR (<5 vs. >= 5 and <3.3 vs. >= 3.3) were performed. RESULTS: Forty-six @entity1 were included in this analysis. Median NLR was 3.3 (0.4-22.8). After a median follow-up of 34 months (13-47 months), the 2-year estimated @entity1349 , @entity3 free survival and locoregional relapse free survival for NLR   <5 vs. >= 5 were 89% vs. 61% (p   =   0.017), 84% vs. 64% (p   =   0.083) and 81% vs. 70% (p   =   0.17) respectively. On univariate analysis NLR   >= 5 (p   =   0.025), older age (p   =   0.01) and ECOG 1 (p   =   0.025) were significant for @entity1349 . CONCLUSION: In this cohort of locally advanced @entity135 @entity1 treated with chemoradiotherapy, pre-treatment NLR   >= 5 was prognostic for mortality. Further studies are required to confirm these results and to assess the interaction with other prognostic factors.
